<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="599">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02219711</url>
  </required_header>
  <id_info>
    <org_study_id>516-001</org_study_id>
    <nct_id>NCT02219711</nct_id>
  </id_info>
  <brief_title>Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer</brief_title>
  <official_title>A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit
      a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR,
      DDR2, TRK and Eph families. In this study, MGCD516 is orally administered to patients with
      advanced solid tumor malignancies to evaluate its safety, pharmacokinetic, metabolism,
      pharmacodynamic and clinical activity profiles.

      During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed; during the
      Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient
      populations.

      Patients anticipated to be enrolled in Phase 1b will be selected based upon having a tumor
      type, including but not limited to, non small cell lung cancer and head and neck cancer
      positive for specific activating MET, NTRK2, NTRK3, or DDR2 mutations, MET or KIT/PDGFRA/KDR
      gene amplification, or selected gene rearrangements involving the MET, RET, AXL, NTRK1, or
      NTRK3 gene loci. In addition patients with clear cell renal cell carcinoma refractory to
      angiogenesis inhibitors or metastatic prostate cancer with bone metastasis will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed.

      During the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected
      patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based
      upon the following cancer diagnosis:

      Non-small cell lung cancer with genetic alterations in MET, AXL, RET, TRK, DDR2, KDR, PDGFRA
      or KIT.

      Head and neck squamous cell carcinoma with genetic alterations in MET.

      Clear cell renal cell carcinoma refractory to angiogenesis inhibitors.

      Metastatic prostate cancer with bone metastases.

      Other cancer diagnosis having a selected genetic alteration in MGCD516 target RTKs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Type of dose limiting adverse event</measure>
    <time_frame>Up to 3 weeks on treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of MGCD516</measure>
    <time_frame>Up to 72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of MGCD516</measure>
    <time_frame>Up to 72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kind of metabolites of MGCD516 in blood plasma</measure>
    <time_frame>Up to 9 weeks on treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of selected marker proteins in blood plasma</measure>
    <time_frame>Up to 9 weeks on treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proteins include VEGF A, soluble VEGF-R2 and soluble MET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients having objective disease response to treatment</measure>
    <time_frame>Up to 1 year on treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>MGCD516</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGCD516 oral capsule, administered in escalating doses in Phase 1, beginning with daily dosing and exploring other regimens as necessary, in 21 or 28 days cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGCD516</intervention_name>
    <description>MGCD516 capsules will be taken with water.</description>
    <arm_group_label>MGCD516</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic or unresectable solid tumor malignancy

          -  Standard treatment is not available

          -  Adequate bone marrow and organ function

        Exclusion Criteria:

          -  History of a significant cardiovascular illness

          -  Prolonged corrected QT (QTc) interval

          -  Left ventricular ejection fraction &lt; 40%

          -  Symptomatic or uncontrolled brain metastases

          -  Other active cancer
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mirati Therapeutics Study Locator Services</last_name>
    <phone>1-844-356-0895 (toll-free)</phone>
    <email>miratistudylocator@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University Center for Advanced Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Research and Treatment Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci K Johnson</last_name>
      <phone>801-587-4744</phone>
      <email>Traci.Johnson@hci.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 15, 2016</lastchanged_date>
  <firstreceived_date>August 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MGCD516</keyword>
  <keyword>MET</keyword>
  <keyword>AXL</keyword>
  <keyword>RET</keyword>
  <keyword>TRK</keyword>
  <keyword>NTRK</keyword>
  <keyword>DDR2</keyword>
  <keyword>KDR</keyword>
  <keyword>VEGFR</keyword>
  <keyword>PDGFRA</keyword>
  <keyword>KIT</keyword>
  <keyword>Tyrosine kinase inhibitor</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Head and neck cancer</keyword>
  <keyword>Renal cell carcinoma</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Phase 1</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
